GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Cyclically Adjusted PB Ratio

Revvity (Revvity) Cyclically Adjusted PB Ratio : 2.69 (As of May. 02, 2024)


View and export this data going back to 1983. Start your Free Trial

What is Revvity Cyclically Adjusted PB Ratio?

As of today (2024-05-02), Revvity's current share price is $101.08. Revvity's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $37.57. Revvity's Cyclically Adjusted PB Ratio for today is 2.69.

The historical rank and industry rank for Revvity's Cyclically Adjusted PB Ratio or its related term are showing as below:

RVTY' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.09   Med: 3.91   Max: 8.04
Current: 2.73

During the past years, Revvity's highest Cyclically Adjusted PB Ratio was 8.04. The lowest was 2.09. And the median was 3.91.

RVTY's Cyclically Adjusted PB Ratio is ranked worse than
63.64% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.975 vs RVTY: 2.73

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Revvity's adjusted book value per share data for the three months ended in Mar. 2024 was $63.522. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $37.57 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Revvity Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Revvity's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Cyclically Adjusted PB Ratio Chart

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.73 6.55 7.70 4.47 2.99

Revvity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.04 3.46 3.10 2.99 2.80

Competitive Comparison of Revvity's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Revvity's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revvity's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Revvity's Cyclically Adjusted PB Ratio falls into.



Revvity Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Revvity's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=101.08/37.57
=2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revvity's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Revvity's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=63.522/129.4194*129.4194
=63.522

Current CPI (Mar. 2024) = 129.4194.

Revvity Quarterly Data

Book Value per Share CPI Adj_Book
201406 18.215 100.560 23.443
201409 18.261 100.428 23.533
201412 18.155 99.070 23.717
201503 18.198 99.621 23.641
201506 18.710 100.684 24.050
201509 18.358 100.392 23.666
201512 18.838 99.792 24.431
201603 18.800 100.470 24.217
201606 19.089 101.688 24.295
201609 19.500 101.861 24.776
201612 19.646 101.863 24.961
201703 20.107 102.862 25.298
201706 22.130 103.349 27.712
201709 23.012 104.136 28.599
201712 22.682 104.011 28.223
201803 23.099 105.290 28.393
201806 22.735 106.317 27.675
201809 23.157 106.507 28.139
201812 23.373 105.998 28.538
201903 23.793 107.251 28.711
201906 24.371 108.070 29.186
201909 24.365 108.329 29.108
201912 25.318 108.420 30.222
202003 24.794 108.902 29.465
202006 26.614 108.767 31.667
202009 28.886 109.815 34.043
202012 33.326 109.897 39.246
202103 35.714 111.754 41.359
202106 37.847 114.631 42.729
202109 55.140 115.734 61.660
202112 56.568 117.630 62.238
202203 56.971 121.301 60.784
202206 56.784 125.017 58.784
202209 55.975 125.227 57.849
202212 58.455 125.222 60.414
202303 63.770 127.348 64.807
202306 63.290 128.729 63.630
202309 62.378 129.860 62.167
202312 63.785 129.419 63.785
202403 63.522 129.419 63.522

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Revvity  (NYSE:RVTY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Revvity Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Revvity's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Revvity (Revvity) Business Description

Traded in Other Exchanges
Address
940 Winter Street, Waltham, MA, USA, 02451
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Executives
Anita Gonzales officer: Please See Remarks 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra officer: Please See Remarks 940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg officer: See Remarks 940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121